KLI
Login
OAK 국가리포지터리
검색
커뮤니티
제목
저자
키워드
발행일
Ulsan Univ. Repository
Browsing by 저자 : 김상위
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
가
나
다
라
마
바
사
아
자
차
카
타
파
하
All
가
나
다
라
마
바
사
아
자
차
카
타
파
하
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
또는 첫 단어:
정렬 기준:
제목
발행일
제출일
정렬:
오름차순
내림차순
결과 수
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
저자 수
All
1
3
5
10
15
20
25
30
35
40
45
50
전체 결과 16건 중 1-16 번을 표시중입니다.
1
Article
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
김상위
;
Benjamin C Creelan
;
Don L Gibbons
;
et al
2021
2
Article
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
김상위
;
Ajlan Atasoy
;
Charuwan Akewanlop
;
et al
2021
3
Article
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer
강진형
;
김동완
;
김봉석
;
et al
2021
4
Article
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
김상위
;
Amy Roshak
;
Byoung Chul Cho
;
et al
2021
5
Article
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study
김상위
;
김우성
;
윤신교
;
et al
2021
6
Article
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
김상위
;
Agnieszka Cseh
;
Christina Raabe
;
et al
2021
7
Article
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
김덕훈
;
김상위
;
윤신교
;
et al
2021
8
Article
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
김상위
;
Adam Pluzanski
;
Alain Vergnenegre
;
et al
2021
9
Article
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
김상위
;
김우성
;
윤신교
;
et al
2021
10
Article
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
김상위
;
Ajlan Atasoy
;
Charuwan Akewanlop
;
et al
2021
11
Article
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
김상위
;
민영주
;
Byoung-Yong Shim
;
et al
2021
12
Article
Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
김상위
;
김좌훈
;
윤신교
;
et al
2021
13
Article
Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
김권일
;
김상위
;
윤신교
;
et al
2021
14
Article
The NHance ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients
김상위
;
Ahmad Awada
;
Alain Thibault
;
et al
2021
15
Article
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
김상위
;
Caicun Zhou
;
Celina Griffin
;
et al
2021
16
Research Laboratory
급성골수성 백혈병에서 CD34와 P-당단백의 발현
이제환
;
김우건
;
김상위
;
et al
1995
1
Anonymous
Login
커뮤니티
제목
저자
키워드
발행일
Guide